Abiopharma

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Alcon Completes Acquisition of LumiThera

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025

New Form 8-K - enGene Holdings Inc. Filed: 2025-09-03 AccNo: 0000950170-25-112674 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

New Form 8-K - Wave Life Sciences Ltd. Filed: 2025-09-03 AccNo: 0001193125-25-194511 Size: 181 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Kiniksa Pharmaceuticals International, plc Filed: 2025-09-03 AccNo: 0001104659-25-086689 Size: 8 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Biogen Highlights Multiple Assets and Indications in Lupus

New Form 8-K - Claritev Corp Filed: 2025-09-03 AccNo: 0001793229-25-000151 Size: 6 MB Item 7.01: Regulation FD Disclosure

New Form 8-K - PALVELLA THERAPEUTICS, INC. Filed: 2025-09-03 AccNo: 0001104659-25-086685 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Shock Top and Auntie Anne’s® Make It Official - Beer Kneads Pretzels

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program